EUROAPI in the news

GuruFocus does not calculate Euroapi's Cyclically Adjusted PS Ratio due to insufficient historical revenue data.

Euroapi experienced a 7% sales decline in FY2025 due to reduced Sanofi sales, but improved core EBITDA by 31% through cost efficiencies, with further sales decline expected in 2026 as it focuses on high-value products.

Working capital per share for Euroapi SA is 940.

Euroapi's third quarter results for 2026 revealed a continued financial downturn, marked by declining revenue, reduced EBITDA margin, and a significant net loss, while its stock price remains in a bearish trend.

Euroapi reported a net loss of EUR 141.5 million in H1 2026 on EUR 356 million in net sales, continuing its FOCUS-27 transformation by divesting assets, streamlining operations, and focusing on cost control and commercial strategy amidst a challenging market.

The document briefly states the free cash flow per share for Euroapi SA and includes copyright details for the CUSIP Database.

Euroapi SA's net debt is reported as 940, with copyright information from 2026.

Euroapi SA's free cash flow is HAN:940 as of 2026-10-06.

Euroapi SA experienced a dilution adjustment.

Sylvia Ortega Martinez was appointed CDMO Scouting & Business Development Director, Americas at EUROAPI to lead business development in the Americas.

Analysts reduced Euroapi's fair value estimate from €1.20 to €1.00 and the company was removed from the S&P Global BMI Index due to revised financial forecasts.

EUROAPI's financial data reveals fluctuating operating cash flow, consistent negative investing cash flow due to high capital expenditures, and varied financing activities, resulting in largely negative free cash flow recently.

Euroapi S.A. (ENXTPA: EAPI) was dropped from the S&P Global BMI Index.

French Minister of State for Industry, Sebastien Martin, visited Euroapi's active pharmaceutical ingredient manufacturing site in Vertolaye on September 15, 2026.

French Minister of State for Industry, Sebastien Martin, visited Euroapi's Vertolaye site, a world leader in active pharmaceutical ingredients.

EuroApi in Vertolaye awaits state support following a ministerial visit that reaffirmed government backing without specific new announcements.

The Minister of State for Industry, Sébastien Martin, visited Euroapi, a world leader in active pharmaceutical ingredients, in Vertolaye on September 15, 2026.

The Minister of State for Industry, Sebastien Martin, visited Euroapi's Vertolaye site, a leading active pharmaceutical ingredient manufacturer, on September 15, 2026.

Citadel Securities Europe has disclosed a net short position in Euroapi shares, according to an AI-generated news brief from Public Technologies (PUBT) based on original content from Euroapi SA.